Clinical trial · Interventional
Trial of Pre-operative Chemoradiotherapy Followed by Surgical Resection in Pancoast Tumors (JCOG 9806)
A Phase II Trial of Pre-operative Chemoradiotherapy Followed by Surgical Resection in Pancoast Tumors: Initial Report of Japan Clinical Oncology Group Trial (JCOG 9806)
NCT00128037CI-TRIAL-00023982completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and efficacy of the trimodality (concurrent chemoradiotherapy followed by surgical resection) approach in superior sulcus tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pulmonary Neoplasm | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| mitomycin C, vindesine, cisplatin and radiotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- 3-year survival rate
Secondary outcomes (3)
- measure
- complete resection rate
- measure
- post-surgical morbidity/mortality
- measure
- local control rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed, pathologically documented non-small cell lung cancer (NSCLC) * Invasion to the first rib or more superior chest wall * Age: 15-74 years old * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Ample organ function * No prior chemo- or radiotherapy * Signed informed consent Exclusion Criteria: * Metastasis to, or involvement of, mediastinal node (N2) * Distant metastasis or dissemination to pleura/pericardium * Active concomitant malignancy * Unstable angina, recent myocardial infarction, heart failure * Uncontrolled diabetes or hypertension * Pregnant or lactating women * Other severe complications
References
Publications (0)
Data not yet available
No reference posted for this study.